Akebia Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Akebia Therapeutics

13/03/2025 13:31

Akebia Therapeutics Inc AKBA.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported breakeven earnings per share.  The mean expectation of three analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -11 cents to -4 cents per share.

Revenue fell 17.3% to $46.50 million from a year ago; analysts expected $37.35 million.

Akebia Therapeutics Inc's reported EPS for the quarter was a loss of 10 cents​.

The company reported a quarterly loss of $22.8 million.

Akebia Therapeutics Inc shares had risen by 1.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.50

This summary was machine generated from LSEG data March 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.08
-0.10
Missed
Sep. 30 2024
-0.06
-0.10
Missed
Jun. 30 2024
-0.05
-0.04
Beat
Mar. 31 2024
-0.08
-0.09
Missed